Akrimax Pharmaceuticals, LLC

akrimax.com

At Akrimax Pharmaceuticals, we manufacture and market pharmaceutical products with unique and meaningful clinical advantages that improve the lives of patients. Our current commercial portfolio is focused in the areas of cardiovascular medicine, endocrinology and pain management. Akrimax is a sales and marketing company. Our mission is to acquire and commercialize under-promoted, under-utilized pharmaceutical products and those in late stage clinical development.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

BIOSERO COLLABORATES WITH ARACELI BIOSCIENCES FOR HIGH-CONTENT ANALYSIS

Biosero, Inc. | February 02, 2022

news image

Biosero, Inc., developer of laboratory automation solutions to orchestrate scientific discoveries, announced a collaboration with Araceli Biosciences that will allow scientists to integrate Araceli’s Endeavor™ high-speed imaging platform into automated workflows controlled by Biosero’s Green Button Go® software suite. The Endeavor platform offers extremely rapid imaging for high-content analysis projects. In just minutes, the instrument can provide subcellula...

Read More

Business Insights

ASTELLAS AND MBC BIOLABS ANNOUNCE ASTELLAS FUTURE INNOVATOR PRIZE TO HELP BIOTECH START-UPS ACCELERATE EARLY DRUG DISCOVERY AND RESEARCH EFFORTS

Astellas Pharma Inc. | September 20, 2022

news image

Astellas Venture Management LLC a wholly-owned venture capital subsidiary of Astellas Pharma Inc. and Mission Bay Capital BioLabs a life-science incubator, today announced their collaboration on the "Astellas Future Innovator Prize" formerly known as the Astellas Golden Ticket competition. Building on over three successful years, the competition offers entrepreneurial scientists or emerging biotechnology start-ups one year's priority usage of MBC BioLabs' state-of-the-art lab f...

Read More

Pharma Tech

AQUAVIT FURTHER PREVAILS AGAINST COUNTERFEITERS IN U S FOLLOWING ITS RECENT VICTORY IN EUROPE

Aquavit Pharmaceuticals, Inc | March 22, 2022

news image

Aquavit Pharmaceuticals, Inc continues to succeed in its intellectual property cases against counterfeiters both domestically and abroad. Following a recent win against counterfeiter U-BioMed, Inc. across the European Union, the U.S. Southern District Court of New York adopted Judge Lehrburger's recommendations that any sanctions related to U-BioMed's deletion of its Instagram account, which blatantly exploited Aquavit's AQUAGOLD product illegally, be folded into the p...

Read More

MAJOR PHARMA COMPANIES INCLUDING NOVARTIS AND MERCK BUILD FEDERATED LEARNING PLATFORM FOR DRUG DISCOVERY

Venturebeat | September 17, 2020

news image

Last June, 10 major pharmaceutical companies — Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, GSK, Institut De Recherches Servier, Janssen, Merck, and Novartis — inked an agreement to build a shared platform called MELLODDY (Machine Learning Ledger Orchestration for Drug Discovery). In partnership with Nvidia, Owkin, and other tech partners, the group sought to leverage techniques like federated learning to collectively train AI on datasets without having to share any pro...

Read More
news image

Business Insights

BIOSERO COLLABORATES WITH ARACELI BIOSCIENCES FOR HIGH-CONTENT ANALYSIS

Biosero, Inc. | February 02, 2022

Biosero, Inc., developer of laboratory automation solutions to orchestrate scientific discoveries, announced a collaboration with Araceli Biosciences that will allow scientists to integrate Araceli’s Endeavor™ high-speed imaging platform into automated workflows controlled by Biosero’s Green Button Go® software suite. The Endeavor platform offers extremely rapid imaging for high-content analysis projects. In just minutes, the instrument can provide subcellula...

Read More
news image

Business Insights

ASTELLAS AND MBC BIOLABS ANNOUNCE ASTELLAS FUTURE INNOVATOR PRIZE TO HELP BIOTECH START-UPS ACCELERATE EARLY DRUG DISCOVERY AND RESEARCH EFFORTS

Astellas Pharma Inc. | September 20, 2022

Astellas Venture Management LLC a wholly-owned venture capital subsidiary of Astellas Pharma Inc. and Mission Bay Capital BioLabs a life-science incubator, today announced their collaboration on the "Astellas Future Innovator Prize" formerly known as the Astellas Golden Ticket competition. Building on over three successful years, the competition offers entrepreneurial scientists or emerging biotechnology start-ups one year's priority usage of MBC BioLabs' state-of-the-art lab f...

Read More
news image

Pharma Tech

AQUAVIT FURTHER PREVAILS AGAINST COUNTERFEITERS IN U S FOLLOWING ITS RECENT VICTORY IN EUROPE

Aquavit Pharmaceuticals, Inc | March 22, 2022

Aquavit Pharmaceuticals, Inc continues to succeed in its intellectual property cases against counterfeiters both domestically and abroad. Following a recent win against counterfeiter U-BioMed, Inc. across the European Union, the U.S. Southern District Court of New York adopted Judge Lehrburger's recommendations that any sanctions related to U-BioMed's deletion of its Instagram account, which blatantly exploited Aquavit's AQUAGOLD product illegally, be folded into the p...

Read More
news image

MAJOR PHARMA COMPANIES INCLUDING NOVARTIS AND MERCK BUILD FEDERATED LEARNING PLATFORM FOR DRUG DISCOVERY

Venturebeat | September 17, 2020

Last June, 10 major pharmaceutical companies — Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, GSK, Institut De Recherches Servier, Janssen, Merck, and Novartis — inked an agreement to build a shared platform called MELLODDY (Machine Learning Ledger Orchestration for Drug Discovery). In partnership with Nvidia, Owkin, and other tech partners, the group sought to leverage techniques like federated learning to collectively train AI on datasets without having to share any pro...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us